[go: up one dir, main page]

EA201892201A1 - Неинвазивная диагностика неалкогольного стеатогепатита - Google Patents

Неинвазивная диагностика неалкогольного стеатогепатита

Info

Publication number
EA201892201A1
EA201892201A1 EA201892201A EA201892201A EA201892201A1 EA 201892201 A1 EA201892201 A1 EA 201892201A1 EA 201892201 A EA201892201 A EA 201892201A EA 201892201 A EA201892201 A EA 201892201A EA 201892201 A1 EA201892201 A1 EA 201892201A1
Authority
EA
Eurasian Patent Office
Prior art keywords
steatopepatitis
alcohol
invasive diagnostics
diagnostics
nash
Prior art date
Application number
EA201892201A
Other languages
English (en)
Inventor
Рафаэль Дартей
Женевьев Кордоннье
Джон Брозек
Эмили Прака
Фуад Бен Судрик
Original Assignee
Женфит
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Женфит filed Critical Женфит
Publication of EA201892201A1 publication Critical patent/EA201892201A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Software Systems (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Computational Mathematics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Probability & Statistics with Applications (AREA)
  • Veterinary Medicine (AREA)

Abstract

Настоящее изобретение относится к новому способу диагностики неалкогольного стеатогепатита (NASH) и классификации индивидуума как потенциального реципиента лечения NASH.
EA201892201A 2016-03-30 2017-03-30 Неинвазивная диагностика неалкогольного стеатогепатита EA201892201A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163048 2016-03-30
PCT/EP2017/057633 WO2017167934A1 (en) 2016-03-30 2017-03-30 Non-invasive diagnostic of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
EA201892201A1 true EA201892201A1 (ru) 2019-03-29

Family

ID=55806131

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892201A EA201892201A1 (ru) 2016-03-30 2017-03-30 Неинвазивная диагностика неалкогольного стеатогепатита

Country Status (14)

Country Link
US (2) US12104209B2 (ru)
EP (2) EP3985126A1 (ru)
JP (2) JP7418959B2 (ru)
KR (1) KR102646698B1 (ru)
CN (1) CN109072302B (ru)
AU (2) AU2017242818B2 (ru)
CA (1) CA3018133A1 (ru)
EA (1) EA201892201A1 (ru)
IL (1) IL261814B2 (ru)
MX (1) MX2018011633A (ru)
PH (1) PH12018502057A1 (ru)
SG (1) SG11201808192RA (ru)
WO (1) WO2017167934A1 (ru)
ZA (1) ZA201807083B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL261814B2 (en) * 2016-03-30 2025-03-01 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
US10624944B2 (en) * 2017-06-19 2020-04-21 Creative Bio-Peptides Inc. Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH)
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
EP3710599B1 (en) * 2017-11-13 2024-07-17 Gilead Sciences, Inc. Method for staging liver fibrosis in nash patients
JP7239139B2 (ja) * 2018-08-03 2023-03-14 国立大学法人金沢大学 肝硬変の診断方法、非アルコール性脂肪肝炎及び肝細胞がんの合併症の診断方法並びに非アルコール性脂肪肝炎及び食道胃静脈瘤の合併症の診断方法
WO2020042114A1 (en) * 2018-08-30 2020-03-05 Terns Pharmaceuticals, Inc. Treating liver disorders
WO2020182952A1 (en) 2019-03-13 2020-09-17 Genfit Diagnosis of non-alcoholic steatohepatitis
MA55592A (fr) 2019-04-10 2022-02-16 Genfit Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1
ES3005085T3 (en) * 2019-04-16 2025-03-13 Genfit Compositions and methods for the stabilization of micro-rna
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
JP7511823B2 (ja) * 2020-01-24 2024-07-08 株式会社The IT Lab ｍｉＲＮＡの発現レベルをがんの確定診断の前のスクリーニングの指標として用いるがんの診断を補助する方法
EP4080221A4 (en) * 2020-02-04 2023-06-28 Denka Company Limited Method for assisting detection of non-alcoholic steatohepatitis
CA3182134A1 (en) * 2020-05-21 2021-11-25 Shionogi & Co., Ltd. Pharmaceutical composition for treating fatty liver disease
EP4237858A1 (en) * 2020-10-30 2023-09-06 Genfit Methods of diagnostic of liver fibrosis
RU2760092C1 (ru) * 2021-03-29 2021-11-22 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью Способ диагностики неалкогольной жировой болезни печени у мужчин европейской популяции при скрининговых обследованиях
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型
US20220340962A1 (en) 2021-04-22 2022-10-27 Genfit Quantitative detection of micro-rnas
KR102521638B1 (ko) * 2021-05-21 2023-04-14 브렉소젠 주식회사 비알코올성 지방간질환의 진단용 마커
EP4355915B1 (en) 2021-06-16 2026-02-04 Genfit Method for nash risk assessment in patients having a metabolic disorder
JP2025511788A (ja) * 2022-04-08 2025-04-16 ジェンフィット 非アルコール性脂肪肝炎の診断の改善
KR20240151900A (ko) 2023-04-11 2024-10-18 고려대학교 산학협력단 장내 균총을 이용한 비알코올성 지방간염 진단용 조성물 및 이의 용도
CN116959734A (zh) * 2023-05-17 2023-10-27 南方医科大学南方医院 一种代谢相关脂肪性肝病发病的预测方法及系统
WO2024240863A1 (en) 2023-05-24 2024-11-28 Genfit Method of diagnostic of liver fibrosis
TW202503059A (zh) 2023-06-06 2025-01-16 法商Ｇｅｎｆｉｔ公司 多重免疫pcr的套組及方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7856319B2 (en) 2005-02-03 2010-12-21 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of alcoholic steato-hepatitis using biochemical markers
WO2012012051A2 (en) * 2010-07-20 2012-01-26 Trustees Of Dartmouth College Method for multicolor codetection of microrna and proteins
WO2012105590A1 (ja) * 2011-02-01 2012-08-09 アステラス製薬株式会社 非アルコール性脂肪肝炎の鑑別マーカー及び当該マーカーを指標とした非アルコール性脂肪肝炎の診断方法
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014049131A1 (en) 2012-09-28 2014-04-03 Université d'Angers Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis
WO2015192854A2 (en) 2014-06-16 2015-12-23 Aarhus Universitet Methods and tools for predicting steatohepatitis
CN104293908A (zh) 2014-06-18 2015-01-21 镇江市第三人民医院 用于检测非酒精性脂肪肝的血清miRNA标志物组合及应用
CN108138232B (zh) * 2015-09-14 2023-07-18 基恩菲特公司 用于诊断和评估非酒精性脂肪性肝炎的方法
IL261814B2 (en) * 2016-03-30 2025-03-01 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
EP3436600A1 (en) 2019-02-06
AU2017242818A1 (en) 2018-10-04
EP3985126A1 (en) 2022-04-20
CN109072302B (zh) 2024-01-16
ZA201807083B (en) 2019-06-26
CN109072302A (zh) 2018-12-21
IL261814A (en) 2018-10-31
BR112018069560A2 (pt) 2019-01-29
JP2022078250A (ja) 2022-05-24
IL261814B2 (en) 2025-03-01
SG11201808192RA (en) 2018-10-30
IL261814B1 (en) 2024-11-01
PH12018502057A1 (en) 2019-06-24
AU2017242818B2 (en) 2023-04-27
NZ746485A (en) 2025-03-28
US20190352715A1 (en) 2019-11-21
US12104209B2 (en) 2024-10-01
CA3018133A1 (en) 2017-10-05
EP3436600C0 (en) 2024-01-17
US20240410010A1 (en) 2024-12-12
JP7418959B2 (ja) 2024-01-22
NZ784641A (en) 2025-03-28
AU2023201802A1 (en) 2023-04-27
KR20180132092A (ko) 2018-12-11
EP3436600B1 (en) 2024-01-17
MX2018011633A (es) 2019-01-10
KR102646698B1 (ko) 2024-03-12
WO2017167934A1 (en) 2017-10-05
JP2019511225A (ja) 2019-04-25
AU2023201802B2 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
EA201892201A1 (ru) Неинвазивная диагностика неалкогольного стеатогепатита
PH12019502283A1 (en) Anti-lag3 antibodies
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EA201890724A1 (ru) Способы диагностики и оценки неалкогольного стеатогепатита
PH12016501366A1 (en) Novel anti-baff antibodies
EA202092609A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
EA201892485A1 (ru) Способ получения соединения диарилтиогидантоина
EA201790413A1 (ru) Антитела против tigit
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
MX2024010027A (es) Anticuerpos contra el vih ampliamente neutralizantes y metodos de uso de ellos.
EA201691648A1 (ru) Способ получения противогрибковых соединений
EA202091259A1 (ru) Способ получения опикапона и его интермедиатов
PH12019502694A1 (en) Anti-trkb antibodies
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
MX2021010475A (es) Diagnostico de esteatohepatitis no alcoholica.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
EA201791389A1 (ru) Способы и композиции антител, направленных против bmp6
EA201990694A1 (ru) Композиции для лечения деменции